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Abstract. Philadelphia chromosome-positive (Ph+) acute 
lymphoblastic leukemia (ALL) is driven by the p190 break-
point cluster region (BCR)-ABL isoform. Although effectively 
targeted by BCR-ABL tyrosine kinase inhibitors (TKIs), ALL 
is associated with a less effective response to TKIs compared 
with chronic myeloid leukemia. Therefore, the identification of 
additional genes required for ALL maintenance may provide 
possible therapeutic targets to aid the eradication of this 
cancer. The present study demonstrated that p190 BCR-ABL is 
able to interact with the deubiquitinase herpesvirus-associated 
ubiquitin‑specific protease (HAUSP), which in turn affects 
p53 protein stability. Notably, the inhibition of HAUSP with 
small molecule inhibitors promoted the upregulation of p53 
protein levels. These results suggest that HAUSP inhibitors 
may harbor clinically relevant implications in the treatment 
of Ph+ ALL.
Introduction
Identification of genes required for tumor maintenance 
often aids therapeutic targeting in the treatment of cancer. 
Philadelphia-positive (Ph+) leukemia is an example of an 
oncogene-addicted disease due to the essential role of 
breakpoint cluster region (BCR)-ABL in the development 
and maintenance of either chronic myeloid leukemia (CML) 
and acute lymphoblastic leukemia (ALL) (1‑4). However, 
inhibition of BCR-ABL via selective TKIs does not result in 
disease eradication (5). Furthermore, the response rates of 
patients with Ph+ ALL to TKIs are much poorer than those of 
patients with CML, with only 50% of patients cured by TKI 
plus chemotherapy and allogenic stem cell transplantation 
programs (6). Therefore, it is mandatory to identify targetable 
pathways that synergize with BCR-ABL in the maintenance 
of Ph+ leukemias and, in particular, ALL. The sustained 
inactivation of tumor suppressors is also involved in tumor 
maintenance. In particular, it was previously demonstrated 
that restoration of p53 in murine models of different forms of 
cancer promotes the induction of cancer-selective apoptosis 
without affecting normal tissues (7). This supports the concept 
that strategies to promote pharmacological reactivation of p53 
may be important in the eradication of cancer. Recently, it was 
observed that BCR‑ABL activates the deubiquitinase HAUSP 
to promote phosphatase and tensin homolog (PTEN) delocal-
ization in CML (8). In addition to targeting PTEN (9), HAUSP 
is able to regulate p53 protein stability (10,11), suggesting that 
the BCR-ABL/HAUSP network may regulate p53 protein 
stability. Due to the requirement of additional therapies, 
particularly against Ph+ ALL, the present study investigated 
the p190 BCR-ABL/HAUSP network and demonstrated that it 
affects p53 stability; therefore, this pathway may be targeted 
by selective inhibitors.
Materials and methods
Cell culture and reagents. HEK 293T cells (ATCC, Manassas, 
VA, USA) were maintained in Dulbecco's modified Eagle's 
medium (Euroclone S.p.A., Pero, Italy) supplemented with 
10% heat-inactivated fetal bovine serum (Sigma-Aldrich, St. 
Louis, MO, USA) and 2 mM glutamine (Euroclone S.p.A.) at 
37˚C in a humidified atmosphere with 5% CO2. The primary 
antibodies used were as follows: Polyclonal rabbit anti‑HAUSP 
(cat no. sc-30164; Santa Cruz Biotechnology, Inc., Dallas, TX, 
USA), monoclonal mouse anti-Myc-Tag (cat no. 2276; Cell 
Signaling Technology, Inc., Danvers, MA, USA), monoclonal 
mouse anti-phospho-tyrosine (cat no. sc-7020; Santa Cruz 
Biotechnology, Inc.), polyclonal rabbit anti-BCR (cat no. 
sc-885; Santa Cruz Biotechnology, Inc.), monoclonal mouse 
anti-phospho-p53 (cat no. 9286; Cell Signaling Technology, 
Inc.), monoclonal mouse anti-p53 (cat no. sc-98; Santa Cruz 
Biotechnology, Inc.) and polyclonal rabbit anti-heat shock 
protein 90α/β (cat no. sc-7947; Santa Cruz Biotechnology, 
Inc.), which was used as a loading control. Secondary goat 
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anti-rabbit and goat anti-mouse antibodies were were from 
Thermoscientific (Waltham, MA, USA), cat nos. 31460 and 
31430, respectively. Primary and secondary antibodies were 
used at 1:1000 and 1:8000 dilutions, respectively.
Plasmid construction, transfection assay and pharmaco‑
logical treatments. Myc-Tag ubiquitin-specific-processing 
protease 7 (HAUSP) wild‑type, Myc‑Tag HAUSP triple mutant 
and p190 BCR/ABL plasmids were constructed as previously 
described (8). To perform transient transfection, the calcium 
phosphate transfection method was used. Briefly, for each 
10-cm dish, 10 µg DNA, 61 µl 2 M CaCl2 and enough distilled 
water to bring the total volume to 0.5 ml was added slowly to 
0.5 ml HEPES buffered saline, which was aerated during the 
addition. After incubating for 20 min at room temperature, the 
mix was added to the plate and incubated for a further 16-24 h 
at 37˚C in a humidified atmosphere with 5% CO2. A total of 
1 or 5 µM imatinib and 4.2 µM P5091 was added for 24 h 
to inactivate p190 BCR/ABL and HAUSP, respectively. The 
same quantity of dimethyl sulfoxide was used for the untreated 
control.
Western blot and immunoprecipitation. Total cell extraction 
was performed using co-immunoprecipitation buffer [150 mM 
NaCl, 1 mM ethylenediaminetetraacetic acid, 50 mM HEPES 
(pH, 7.5), 1% Triton and 10% glycerol] supplemented with 
Figure 1. (A) Western immunoblotting using anti‑pTyr antibody. HEK 293T cells were transfected with the HAUSP WT or HAUSP TM (Y243F/Y878F/Y947F) 
in the presence of p190 BCR‑ABL. Immunoprecipitation was performed with anti‑Myc antibodies (HAUSP). (B) Immunoprecipitation of Myc‑HAUSP and 
anti‑pTyr immunoblot following treatment with 1 or 5 µM imatinib for 24 h; (C) Left panel: Western immunoblot of HEK 293T cells expressing p190 BCR‑ABL 
and Myc‑HAUSP. Cells were treated with P5091 and imatinib for 24 h at concentration of 4.2 and 5 µM respectively, and were subsequently analyzed for 
expression of p53 and p‑p53. Right panel: Quantification and statistical analysis of p-p53 protein (**P=0.0018 and *P=0.0371). P-values were calculated by a 
two-tailed t‑test. p‑, phosphorylated; Tyr, tyrosine; HAUSP, herpesvirus‑associated ubiquitin‑specific protease; GAPDH, glyceraldehyde 3-phosphate dehydro-
genase; IP, immunoprecipitation; WT, wild‑type; TM, triple mutant; IM, imatinib.
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protease inhibitor (cat no. 036K4082; Sigma-Aldrich) and 
a phosphatase cocktail composed of PMSF and Na3VO4. 
Following quantification by Bio‑Rad Protein assay (Bio‑Rad 
Laboratories, Inc., Hercules, CA, USA), 30 µg protein extract 
was denatured, reduced, separated by 8% sodium dodecyl 
sulfate polyacrylamide gel electrophoresis and electropho-
retically transferred onto nitrocellulose membranes. The 
membranes were subsequently quenched with 5% bovine 
serum albumin and probed overnight with primary antibodies. 
Protein detection was performed using peroxidise-conjugated 
secondary antibodies and enhanced chemiluminescence 
reagent (cat no. 170-5060; Bio-Rad Laboratories, Inc.), 
according to the manufacturer's protocol. For immunoprecipi-
tation experiments, 500 µg protein extracts were precleared 
with agarose-conjugated normal immunoglobulin G (Santa 
Cruz Biotechnology, Inc.) for 1 h at 4˚C and then precipitated 
overnight at 4˚C with anti‑Myc‑Tag antibody along with 
Dynabeads® protein G. The immunoprecipitate samples were 
then resolved by western blot analysis. Image acquisition and 
analysis was performed using ImageLab software (Bio-Rad 
Laboratories, Inc.).
Statistical analysis. Two-sided Student’s t-test or two way 
ANOVA with Bonferroni post-test were calculated using 
GraphPad Prism v5.0 (GraphPad Software, Inc., La Jolla, 
CA, USA). P<0.05 was considered to indicate a statistically 
significant difference.
Results
Expression of HAUSP triple mutant reduces HAUSP phos‑
phorylation. To investigate whether p190 BCR-ABL retains 
the capability to interact with HAUSP and to promote HAUSP 
phosphorylation, p190 BCR‑ABL and Myc‑HAUSP‑expressing 
vectors were transfected into HEK 293T cells. At 48 h 
post-transfection, the HEK 293T cells were lysed, and then 
immunoprecipitation with anti‑Myc‑Tag antibody (HAUSP) 
was performed. As presented in Fig. 1A, HAUSP was phos-
phorylated on tyrosine residues by p190 BCR-ABL. Notably, 
expression of the HAUSP triple mutant (Y243F/Y878F/Y947F), 
which bears mutants on three tyrosine residues phosphory-
lated by p210 BCR/ABL (8), reduced HAUSP phosphorylation 
levels in HEK 293T when compared to those of HAUSP WT, 
as observed with p210 BCR/ABL (8).
BCR‑ABL inhibition is associated with HAUSP dephosphory‑
lation, and inhibition and deletion of HAUSP is associated 
with p53 destabilization. To test the contribution of BCR-ABL 
tyrosine kinase in the phosphorylation of HAUSP, transfected 
HEK 293T cells were treated with varying concentrations 
of the BCR-ABL TKI, imatinib. The results demonstrated 
that P190 BCR-ABL inhibition, as observed with p210 BCR/
ABL (8), was associated with HAUSP dephosphorylation 
(Fig. 1B). In addition to the ability of HAUSP to deubiquiti-
nate PTEN and the relevance of the BCR-ABL/HAUSP/PTEN 
network in CML, HAUSP is also able to target p53 (10,11). 
In particular, HAUSP has been previously reported to inter-
fere with the mouse double minute 2 homolog (MDM2)/p53 
network causing p53 destabilization (10,11). The results of the 
present study were consistent with these previous findings, 
demonstrating that the deletion and inhibition of HAUSP was 
associated with p53 upregulation (Fig. 1C).
Imatinib and P5091 promote p53 upregulation and phos‑
phorylation. To test whether HAUSP inhibition is able to 
regulate p53 protein stability downstream of BCR-ABL, 
p190 BCR-ABL-transfected cells were treated with imatinib 
and the HAUSP inhibitor, P5091. As presented in Fig. 1C, 
imatinib was able to promote p53 upregulation; however, the 
greatest increase in p53 protein expression and phosphorylation 
on Ser15, a marker of functionally active p53, was observed 
following incubation with the HAUSP inhibitor (P5091) with 
subsequent apoptosis induction (data not shown).
Discussion
Identification of signaling transduction pathways that function 
in the maintenance of cancer are extremely important from a 
therapeutic standpoint, and targeting of these pathways may aid 
the eradication of cancer. ALL therapy requires the detection 
of additional targets, not only to achieve disease abolishment, 
but also to achieve a more positive overall response to TKIs. 
The present study identified the p190‑BCR‑ABL/HAUSP/p53 
network as a challenging, targetable pathway that promotes the 
regulation of p53 protein stability. The data obtained from the 
present study did not demonstrate whether p53 upregulation 
is directly regulated by HAUSP activity or is dependent on 
the more complex BCR/ABL/HAUSP/MDM2/p53 network, 
but the upregulation in p53 levels supports the assessment of 
HAUSP inhibitors in the clinical setting.
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